References
- Tsiara S, Pappas K, Boutsis D, et al. New oral anticoagulants: should they replace heparins and warfarin? Hellenic J Cardiol 2011;52:52-67
- Landman GW, Gans ROB. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2011;364:1178; author reply 1178
- Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52
- Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799-808
- Büller HR, Décousus H, Grosso Ma, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369:1406-15
- Agnelli G, Becattini C, Franco L. New oral anticoagulants for the treatment of venous thromboembolism. Best practice & research. Clin Haematol 2013;26:151-61
- U.S. Food and Drug Administration. FDA expands use of Xarelto to treat, reduce recurrence of blood clots. Maryland, 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm326654.htm. Accessed February 2015
- Boehringer Ingelheim. FDA Approves Pradaxa® (dabigatran etexilate mesylate) for treatment and reduction in the risk of recurrence of deep venous thrombosis and pulmonary embolism. Maryland, 2014. http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2014/04-07-14-fda-approves-pradaxa-dabigatran-etexilate-mesylate-treatment-reduction-risk-of-recurrence-deep-venous-thrombosis-pulmonary-embolism.html. Accessed February 2015
- Bristol-Myers Squibb. U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the reduction in the risk of recurrent DVT and PE following initial therapy BMS Newsroom. Assessed
- U.S. Food and Drug Administration. FDA approves anti-clotting drug Savaysa. Maryland, 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm429523.htm. Accessed February 2015
- Deitelzweig SB, Johnson BH, Lin J, et al. Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. Am J Hematol 2011;86:217-20
- Beckman MG, Hooper WC, Critchley SE, et al. Venous thromboembolism: a public health concern. Am J Prev Med 2010;38(4 Suppl):S495-501
- Dobesh PP. Economic implications of inadequate treatment of venous thromboembolism and potential solutions. J Pharm Pract 2014;27:178-86
- Merli GJ, Hollander JE, Lefebvre P, et al. Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxaban. Hosp Pract (1995) 2015;43:85-93
- Cohen J. Statistical power analysis for the behavioral sciences. Toronto: Academic Press, Inc, 1977. p 19-24
- Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol 2001;54:387-98
- Austin PC. Using the Standardized Difference To Compare The Prevalence Of A Binary Variable Between Two Groups In Observational Research. Commun Stat Simul Comput 2009;38:1228-34
- Lefebvre P, Coleman CI, Bookhart BK, et al. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism. J Med Econ 2014;17:52-64
- Seaman CD, Smith KJ, Ragni MV. Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective. Thromb Res 2013;132:647-51
- Laliberté F, Pilon D, Raut MK, et al. Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation? Curr Med Res Opin 2014;30:645-53
- Fonseca E, Walker DR, Hill J, et al. Abstract 282: Dabigatran Etexilate Is Associated With Shorter Hospital Length Of Stay Compared To Warfarin In Patients With Nonvalvular Atrial Fibrillation. Circul Cardiovasc Qual Outcomes 2012;5:A282
- Cowper PA, Pan W, Anstrom K, Stafford J, et al. Apixaban reduces hospitalization in patients with atrial fibrillation: an analysis of the effect of Apixaban therapy on resource use in the Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation trial. J Am Coll Cardiol 2013;61:E1576
- Laliberté F, Pilon D, Raut MK, et al. Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation? Curr Med Res Opin 2014;30:1521-8